Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

Published:2014-04-03 Issue:14 Volume:123 Page:2220-2228
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lundberg Pontus¹,Karow Axel¹,Nienhold Ronny¹,Looser Renate¹,Hao-Shen Hui¹,Nissen Ina²,Girsberger Sabine³,Lehmann Thomas³,Passweg Jakob³,Stern Martin¹³,Beisel Christian²,Kralovics Robert⁴⁵,Skoda Radek C.¹³

Affiliation:

1. Experimental Hematology, Department of Biomedicine, University Hospital of Basel, Basel, Switzerland;

2. Department of Biosystems Science and Engineering, Swiss Federal Institute of Technology, Zurich, Switzerland;

3. Division of Hematology, University Hospital Basel, Basel, Switzerland;

4. CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria; and

5. Division of Hematology and Blood Coagulation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Abstract

Key Points The total number of somatic mutations was inversely correlated with survival and risk of leukemic transformation in MPN. The great majority of somatic mutations were already present at MPN diagnosis, and very few new mutations were detected during follow-up.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/14/2220/1375027/2220.pdf

Reference35 articles.

1. A gain-of-function mutation of JAK2 in myeloproliferative disorders.;Kralovics;N Engl J Med,2005

2. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.;Levine;Cancer Cell,2005

3. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.;James;Nature,2005

4. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

5. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.;Kralovics;Blood,2006

Cited by 496 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study;Leukemia;2024-02-06

2. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements;Cancers;2024-01-25

3. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms;Blood Cancer Journal;2024-01-04

4. Pharmacological reactivation of p53 in the era of precision anticancer medicine;Nature Reviews Clinical Oncology;2023-12-15

5. Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study;Oncohematology;2023-12-08